Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2016-09-21 to 2021-07-27
ROUNDS
3
joined, none as lead
ROUNDS JOINED · USD
$270.2M
across 3 rounds
CO-INVESTORS
24
named beside it
Named on 3 rounds in the feed, most often in Biotech.
Rounds from 2016-09-21 to 2021-07-27
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $84M | 2018-08-10 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $33.2M | 2016-09-21 | [ PART ] |